Genentech, Inc.

Constellation Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Terns, Inc.

Metabasis Therapeutics, Inc.

Unity Biotechnology, Inc.

Oric Pharmaceuticals, Inc.

Metabasas Therapeutics, Inc.

F. Hoffmann-la Roche Ag

F Anthony Romero

Steven R Magnuson

Vickie Hsiao-Wei Tsui

Brian K Albrecht

Alexander M Taylor

Christopher G Nasveschuk

Randall Halcomb

Thorsten A Kirschberg

Terry Crawford

Alexandre Cote

Yingzi Xu

Martijn Fenaux

Christopher T Jones

Corey Reeves

Jianming Bao

Mark Edward Zak

Kwong Wah Lai

Fei Wang

Qun Dang

Iyassu Sebhat

Richard Pastor

Daniel J Burdick

Paul Gibbons

Dariusz Wodka

Yun-Xing Cheng

Ping Lan

Hongjian Jiang

Tony Gibson

Huagang Lu

Sarah Bronner

Yves LeBlanc

Yong Tang

Patrick Cyr

De Michael Chung

Gergely M Makara

Michael Charles Hewitt

Kevin X Chen

Martin Duplessis

Shumei Wang

John Wai

Jeremy M Murray

Wei Li

Jun Liang

Xiaohui Du

Jinlong Jiang

Stephane Ciblat

Anne-Marie Beausoleil

Victor S Gehling

Steven F Bellon

Remi-Martin Laberge

Guiling Zhao

Po-Wai Yuen

Brett C Bookser

Ahmet Kekec

Jared Moore

Les A Dakin

Lea Constantineau-Forget

Kejia Wu

Hiroyuki Kawai

Ryan Hudson

Daniel Cashion

Joanne Tan

Andrew Charles Good

Gary W Luehr

James Richard Jr Kiefer

Marc Adler

Andy Kassick

David Wilson

Amit Nayyar

Bing-Yan Zhu

Paul E Finke

Yves Leblanc

Feroze Ujjainwalla

Harold B Wood

Birong Zhang

James John Crawford

Weiguo Liu

Emily J Hanan

Simon Charles Goodacre

Joseph Leslie Duffy

Naomi S Rajapaksa

Gregory Hamilton

Feng Ye

Edward C Sherer

Terry Kellar

Alexandre Côté

Sriram Tyagarajan

Debra L Ondeyka

Steven Elliot Kauder

Yi Zang

Marian C Bryan

Remond Moningka

Zahid Hussain

James Richard Kiefer, Jr

Revathi Reddy Katipally

Jessica Grandner

Jiangpeng Liao

Jackson G Egen

Michael A Plotkin

Aaron Zwicker

The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.

Compounds as GLP-1R agonists

Provided herein are compounds, preferably (R)-N-(4-(chlorodifluoromethoxy) phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide having the Formula I or a pharmaceutically acceptable salt or tautomer thereof, that inhibits tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.

(r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Thyroid hormone receptor beta agonist compounds

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Polo like kinase 4 inhibitors

Compounds of formula (I) wherein R, R, R, R, Rand Rare as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases

Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease. Intermediates such as compounds of Formula (S23), which are useful in the synthesis of compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, are also provided.

Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity

Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Therapeutic compounds, compositions and methods of use thereof

Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.

Pyrazolochlorophenyl compounds, compositions and methods of use thereof

The present invention relates to a compound formula (I): and to salts thereof, wherein R, RX, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Therapeutic compounds and uses thereof

Growing community of inventors

Redwood City, CA, United States of America

F Anthony Romero